Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 2, 2013, Pages 549-554

  Wang, Yan Qiu ^a   Yan, Qin ^a   Zhang, Jia Rong ^a   Li, Shuang Di ^a   Yang, Yi Xia ^a   Wan, Xiao Ping ^b  

^a First Hosp Shanghai Text Bur   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Biomarker; BRCA1; Cancer progression; Early diagnosis; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; OVARY DISEASE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BRCA1 PROTEIN; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84875247647     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01979.x     Document Type: Article

References (25)

1. Dulaimi E, Hillinck J, Ibanez de Caceres I et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10: 6189-6193.
2. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
3. Lee MN, Tseng RC, Hsu HS et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007; 13: 832-838.
4. Kissel CK, Schadendorf D, Röckmann H. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific. Melanoma Res 2006; 16: 527-535.
5. Zhong Q, Wen YJ, Yang HS et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 2008; 19: 1584-1591.
6. Quinn JE, Carser JE, James CR et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113: 134-142.
7. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
8. Birgisdottir V, Stefansson OA, Bodvarsdottir SK et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8: R38.
9. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 2002; 21: 8994-9007.
10. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97: 2187-2195.
11. Wiley A, Katsaros D, Chen H et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 2006; 107: 299-308.
12. Wang YQ, Zhang JR, Li SD et al. Aberrant methylation of BRCA1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway. Cancer Sci 2010; 101: 1618-1623.
13. Wei SH, Chen CM, Strathdee G et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8: 2246-2252.
14. Ibanez de Caceres I, Battagli C, Esteller M et al. Tumor cellspecific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64: 6476-6481.
15. Sellar GC, Watt KP, Rabiasz GJ et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34: 337-343.
16. Li M, Balch C, Montgomery JS et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009; 8: 34.
17. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast cancer and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
18. DiNardo DN, Butcher DT, Robinson DP et al. Functional analysis of CpG methylation in the BRCA1promoter region. Oncogene 2001; 20: 5331-5340.
19. Davis PL, Miron A, andersen LM et al. Isolation and initial characterization of the BRCA2 promoter. Oncogene 1999; 18: 6000-6012.
20. Ludwig DL, Chen F, Peterson SR et al. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene 1997; 199: 181-194.
21. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999; 96: 4983-4988.
22. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17: 1807-1812.
23. Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002; 62: 4151-4156.
24. Rathi A, Virmani AK, Schorge JO et al. Methylation profiles of sporadic ovarian tumours and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002; 8: 3324-3331.
25. Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol 2011; 780: 277-291.